Le Registre des lobbyistes
Johnson & Johnson (Canada) Inc.
Objets | Détails | Catégories |
---|---|---|
Développement économique, Santé, Industrie, Propriété intellectuelle, Commerce international
|
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
|
Politique ou Programme
|
Affaires autochtones, Santé
|
Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas.
|
Politique ou Programme
|
Santé, Industrie
|
Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
|
Politique ou Programme, Proposition législative, Projet de loi ou résolution
|
Santé, Industrie, Propriété intellectuelle
|
Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products.
|
Politique ou Programme
|
Santé, Industrie
|
Communication to officials on labelling and product monographs.
|
Règlement
|
Santé
|
COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.
|
Politique ou Programme
|
Développement économique, Santé, Industrie, Commerce intérieur, Recherche et développement, Sciences et technologies, Impôts et finances
|
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada.
|
Politique ou Programme, Proposition législative, Projet de loi ou résolution
|
Santé, Industrie
|
Food and Drugs Act: Delays in product approvals and changes to existing products.
|
Proposition législative, Projet de loi ou résolution, Politique ou Programme
|
Santé, Industrie, Propriété intellectuelle
|
Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
|
Proposition législative, Projet de loi ou résolution, Règlement, Politique ou Programme
|
Développement économique, Santé, Industrie, Propriété intellectuelle
|
Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations.
|
Règlement, Proposition législative, Projet de loi ou résolution, Politique ou Programme
|
Développement économique, Santé, Industrie, Commerce intérieur, Recherche et développement, Sciences et technologies
|
Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
|
Politique ou Programme
|
Santé, Industrie
|
Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information.
|
Proposition législative, Projet de loi ou résolution, Règlement
|
Santé
|
Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program.
|
Politique ou Programme, Proposition législative, Projet de loi ou résolution
|
Développement économique, Santé, Industrie, Commerce international, Impôts et finances
|
Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils
|
Politique ou Programme
|
Environnement, Santé, Industrie
|
Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies.
|
Proposition législative, Projet de loi ou résolution
|